Amgen

(NASDAQ: AMGN)
Health Care  |  Biotechnology
253.01 1.12 0.44%
Stock Price | May 25, 2022, 4 p.m.
0 Followers
Bid: 247.66
Ask: 254.5
Prev. Close: 251.89
52 Week Low: 198.64
52 Week High: 258.45
PE Ratio: 24.976308
Dividend Yield: 307.0%

Company Summary

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more Read less

Recently Viewed Tickers

Free THE WEEKLY TOP 10

7 months ago
1 year ago
2 years ago